![]() ![]() In such circumstances, the patient must be closely monitored. In the circumstance in which commencing with oral opioids is not considered possible and Fencino is considered to be the only appropriate treatment option for opioid-naïve patients, only the lowest starting dose (ie, 12 mcg/h) should be considered. To prevent overdose it is recommended that opioid-naïve patients receive low doses of immediate-release opioids (eg, morphine, hydromorphone, oxycodone, tramadol, and codeine) that are to be titrated until an analgesic dosage equivalent to Fencino with a release rate of 12 mcg/h or 25 mcg/h is attained. Alternative routes of administration (oral, parenteral) should be considered. Generally, the transdermal route is not recommended in opioid-naïve patients. The dosage may subsequently be titrated upwards or downwards, if required, in increments of either 12 or 25 mcg/h to achieve the lowest appropriate dosage of Fencino depending on response and supplementary analgesic requirements. To convert opioid-tolerant patients from oral or parenteral opioids to Fencino refer to Equianalgesic potency conversion below. Other factors to be considered are the current general condition and medical status of the patient, including body size, age, and extent of debilitation as well as degree of opioid tolerance. It is recommended that Fencino be used in patients who have demonstrated opioid tolerance. The appropriate initiating dose of Fencino should be based on the patient's current opioid use. The patches are designed to deliver approximately 12, 25, 50, 75, and 100 mcg/h fentanyl to the systemic circulation, which represent about 0.3, 0.6, 1.2, 1.8, and 2.4 mg per day respectively. The lowest effective dose should be used. Date of first authorisation/renewal of the authorisationįencino doses should be individualised based upon the status of the patient and should be assessed at regular intervals after application. 6.6 Special precautions for disposal and other handling.4.7 Effects on ability to drive and use machines.4.5 Interaction with other medicinal products and other forms of interaction.4.4 Special warnings and precautions for use.4.2 Posology and method of administration.Show table of contents Hide table of contents ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |